178 related articles for article (PubMed ID: 26501112)
21. Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Ouyang B; Zhou F; Zhen L; Peng Y; Sun J; Chen Q; Jin X; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Nov; 146():147-153. PubMed ID: 28881311
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.
Burns RN; Hendrix CW; Chaturvedula A
J Clin Pharmacol; 2015 Jun; 55(6):629-38. PubMed ID: 25581815
[TBL] [Abstract][Full Text] [Related]
24. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
[TBL] [Abstract][Full Text] [Related]
26. Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.
Beadle JR; Aldern KA; Zhang XQ; Valiaeva N; Hostetler KY; Schooley RT
Antiviral Res; 2019 Nov; 171():104614. PubMed ID: 31550449
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
[TBL] [Abstract][Full Text] [Related]
28. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
[TBL] [Abstract][Full Text] [Related]
30. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
31. A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.
Jayachandran P; Garcia-Cremades M; Vučićević K; Bumpus NN; Anton P; Hendrix C; Savić R
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):179-187. PubMed ID: 33547874
[TBL] [Abstract][Full Text] [Related]
32. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
33. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
34. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
35. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
36. Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
Shen Z; Rodriguez-Garcia M; Patel MV; Bodwell J; Kashuba ADM; Wira CR
Sci Rep; 2017 Dec; 7(1):17697. PubMed ID: 29255206
[TBL] [Abstract][Full Text] [Related]
37. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
Rodriguez-Garcia M; Patel MV; Shen Z; Bodwell J; Rossoll RM; Wira CR
Sci Rep; 2017 Apr; 8():45725. PubMed ID: 28368028
[TBL] [Abstract][Full Text] [Related]
38. Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Ngandu NK; Carlson JM; Chopera DR; Ndabambi N; Abdool Karim Q; Abdool Karim S; Williamson C
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):43-47. PubMed ID: 28797020
[TBL] [Abstract][Full Text] [Related]
39. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
[TBL] [Abstract][Full Text] [Related]
40. Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.
Seifert SM; Castillo-Mancilla JR; Erlandson K; Morrow M; Gandhi M; Kuncze K; Horng H; Zheng JH; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):295-298. PubMed ID: 29189417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
